Positive results for ROS1 on Crizotinib

Objective responses occurred in 72% of patients. 50 patients on trial. The PFS WAS 19.2 months. REMARKABLE!

Here is an article in the NEJM.


Other articles:



Look at the attached comment also.

This entry was posted in crizotinib - Xalkori from Pfizer. Bookmark the permalink.

One Response to Positive results for ROS1 on Crizotinib

Leave a Reply